HU226471B1 - Direct ortho-metalation process for the synthesis of 5-(2-substituted-phenyl)-tetrazol derivatives - Google Patents
Direct ortho-metalation process for the synthesis of 5-(2-substituted-phenyl)-tetrazol derivatives Download PDFInfo
- Publication number
- HU226471B1 HU226471B1 HU0004227A HUP0004227A HU226471B1 HU 226471 B1 HU226471 B1 HU 226471B1 HU 0004227 A HU0004227 A HU 0004227A HU P0004227 A HUP0004227 A HU P0004227A HU 226471 B1 HU226471 B1 HU 226471B1
- Authority
- HU
- Hungary
- Prior art keywords
- formula
- compound
- mmol
- process according
- compounds
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 39
- -1 5-(2-substituted-phenyl)-tetrazol Chemical class 0.000 title claims description 19
- 230000015572 biosynthetic process Effects 0.000 title description 4
- 238000003786 synthesis reaction Methods 0.000 title description 3
- 238000007122 ortho-metalation reaction Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 53
- 229910052751 metal Inorganic materials 0.000 claims description 40
- 239000002184 metal Substances 0.000 claims description 40
- RKMGAJGJIURJSJ-UHFFFAOYSA-N 2,2,6,6-tetramethylpiperidine Chemical group CC1(C)CCCC(C)(C)N1 RKMGAJGJIURJSJ-UHFFFAOYSA-N 0.000 claims description 21
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical group CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 9
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 230000003197 catalytic effect Effects 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 125000001841 imino group Chemical group [H]N=* 0.000 claims description 5
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical group [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 claims description 5
- 125000006239 protecting group Chemical group 0.000 claims description 5
- 239000007858 starting material Substances 0.000 claims description 5
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 4
- 239000002081 C09CA05 - Tasosartan Substances 0.000 claims description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 4
- 229910052794 bromium Inorganic materials 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 239000000460 chlorine Substances 0.000 claims description 4
- 229940043279 diisopropylamine Drugs 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 229960000651 tasosartan Drugs 0.000 claims description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical group 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 3
- 229910052739 hydrogen Inorganic materials 0.000 claims description 3
- 229910052740 iodine Inorganic materials 0.000 claims description 3
- 239000011630 iodine Substances 0.000 claims description 3
- 150000003335 secondary amines Chemical class 0.000 claims description 3
- ADXGNEYLLLSOAR-UHFFFAOYSA-N tasosartan Chemical compound C12=NC(C)=NC(C)=C2CCC(=O)N1CC(C=C1)=CC=C1C1=CC=CC=C1C=1N=NNN=1 ADXGNEYLLLSOAR-UHFFFAOYSA-N 0.000 claims description 3
- FMRWQLAJBBKXDM-UHFFFAOYSA-N 2,2,5,5-tetramethylpyrrolidine Chemical group CC1(C)CCC(C)(C)N1 FMRWQLAJBBKXDM-UHFFFAOYSA-N 0.000 claims description 2
- ZWXQPERWRDHCMZ-UHFFFAOYSA-N 2-methyl-n-propan-2-ylpropan-2-amine Chemical group CC(C)NC(C)(C)C ZWXQPERWRDHCMZ-UHFFFAOYSA-N 0.000 claims description 2
- 125000003368 amide group Chemical group 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- OBYVIBDTOCAXSN-UHFFFAOYSA-N n-butan-2-ylbutan-2-amine Chemical group CCC(C)NC(C)CC OBYVIBDTOCAXSN-UHFFFAOYSA-N 0.000 claims description 2
- FUUUBHCENZGYJA-UHFFFAOYSA-N n-cyclopentylcyclopentanamine Chemical group C1CCCC1NC1CCCC1 FUUUBHCENZGYJA-UHFFFAOYSA-N 0.000 claims description 2
- CATWEXRJGNBIJD-UHFFFAOYSA-N n-tert-butyl-2-methylpropan-2-amine Chemical group CC(C)(C)NC(C)(C)C CATWEXRJGNBIJD-UHFFFAOYSA-N 0.000 claims description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims 1
- JTHVJUYIIQKFHH-UHFFFAOYSA-N n-cyclohexylcyclohexanamine;2,2,6,6-tetramethylpiperidine Chemical group CC1(C)CCCC(C)(C)N1.C1CCCCC1NC1CCCCC1 JTHVJUYIIQKFHH-UHFFFAOYSA-N 0.000 claims 1
- JKWKFBUUNGGYBP-UHFFFAOYSA-N n-cyclopropylcyclopropanamine Chemical group C1CC1NC1CC1 JKWKFBUUNGGYBP-UHFFFAOYSA-N 0.000 claims 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 24
- 239000011541 reaction mixture Substances 0.000 description 21
- 238000003756 stirring Methods 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 13
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 238000010992 reflux Methods 0.000 description 12
- MARUHZGHZWCEQU-UHFFFAOYSA-N 5-phenyl-2h-tetrazole Chemical compound C1=CC=CC=C1C1=NNN=N1 MARUHZGHZWCEQU-UHFFFAOYSA-N 0.000 description 11
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 11
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 10
- VYDLZOWMGPAVLN-UHFFFAOYSA-N 5-(2-methyl-1-phenylpropan-2-yl)-2h-tetrazole Chemical compound N1=NNN=C1C(C)(C)CC1=CC=CC=C1 VYDLZOWMGPAVLN-UHFFFAOYSA-N 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 150000004795 grignard reagents Chemical class 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 8
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 8
- 229940123413 Angiotensin II antagonist Drugs 0.000 description 7
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 7
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 229910052725 zinc Inorganic materials 0.000 description 6
- 239000011701 zinc Substances 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 229910052749 magnesium Inorganic materials 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000011592 zinc chloride Substances 0.000 description 4
- 235000005074 zinc chloride Nutrition 0.000 description 4
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 3
- 239000002083 C09CA01 - Losartan Substances 0.000 description 3
- 239000007818 Grignard reagent Substances 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical group [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 229910052744 lithium Inorganic materials 0.000 description 3
- 229960004773 losartan Drugs 0.000 description 3
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 2
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 150000004791 alkyl magnesium halides Chemical class 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 229960002198 irbesartan Drugs 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 150000002641 lithium Chemical group 0.000 description 2
- 150000002642 lithium compounds Chemical class 0.000 description 2
- 150000002900 organolithium compounds Chemical class 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 150000003053 piperidines Chemical class 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960004699 valsartan Drugs 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- CMSMSYXAJAPWOS-UHFFFAOYSA-N 5-phenyl-2h-tetrazole;sodium Chemical compound [Na].C1=CC=CC=C1C1=NNN=N1 CMSMSYXAJAPWOS-UHFFFAOYSA-N 0.000 description 1
- UOWPUJVDWMDXNL-UHFFFAOYSA-N 5-tert-butyl-1-phenyltetrazole Chemical compound CC(C)(C)C1=NN=NN1C1=CC=CC=C1 UOWPUJVDWMDXNL-UHFFFAOYSA-N 0.000 description 1
- JSVMKZJNKXEGIN-UHFFFAOYSA-N 6h-pyrido[2,3-d]pyrimidin-7-one Chemical compound C1=NC=NC2=NC(=O)CC=C21 JSVMKZJNKXEGIN-UHFFFAOYSA-N 0.000 description 1
- RIGIQZIXVFCURM-UHFFFAOYSA-N 8-[(4-bromophenyl)methyl]-2,4-dimethyl-5,6-dihydropyrido[2,3-d]pyrimidin-7-one Chemical compound C12=NC(C)=NC(C)=C2CCC(=O)N1CC1=CC=C(Br)C=C1 RIGIQZIXVFCURM-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- NICRXUZBFPUWQZ-UHFFFAOYSA-N C(C)(C)(C)C1=C(C=CC=C1)[Mg]C1=NN=NN1 Chemical compound C(C)(C)(C)C1=C(C=CC=C1)[Mg]C1=NN=NN1 NICRXUZBFPUWQZ-UHFFFAOYSA-N 0.000 description 1
- 239000002053 C09CA06 - Candesartan Substances 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical group [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 101100006584 Mus musculus Clnk gene Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical group [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical group [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 description 1
- 229960000932 candesartan Drugs 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Chemical group 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- CCERQOYLJJULMD-UHFFFAOYSA-M magnesium;carbanide;chloride Chemical compound [CH3-].[Mg+2].[Cl-] CCERQOYLJJULMD-UHFFFAOYSA-M 0.000 description 1
- SCEZYJKGDJPHQO-UHFFFAOYSA-M magnesium;methanidylbenzene;chloride Chemical compound [Mg+2].[Cl-].[CH2-]C1=CC=CC=C1 SCEZYJKGDJPHQO-UHFFFAOYSA-M 0.000 description 1
- 150000002780 morpholines Chemical class 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 150000008048 phenylpyrazoles Chemical class 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003536 tetrazoles Chemical group 0.000 description 1
- 229910052718 tin Chemical group 0.000 description 1
- 125000004665 trialkylsilyl group Chemical group 0.000 description 1
- ACWBQPMHZXGDFX-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=NN1 ACWBQPMHZXGDFX-QFIPXVFZSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F3/00—Compounds containing elements of Groups 2 or 12 of the Periodic Table
- C07F3/02—Magnesium compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT97MI001544A IT1292437B1 (it) | 1997-06-30 | 1997-06-30 | Processo di orto-metallazione utile per la sintesi di 1 - tetrazol- 5-il) benzeni 2-sostituiti |
| PCT/EP1998/003969 WO1999001459A1 (en) | 1997-06-30 | 1998-06-29 | Ortho-metalation process for the synthesis of 2-substituted-1-(tetrazol-5-yl)benzenes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| HUP0004227A2 HUP0004227A2 (hu) | 2001-06-28 |
| HUP0004227A3 HUP0004227A3 (en) | 2003-03-28 |
| HU226471B1 true HU226471B1 (en) | 2008-12-29 |
Family
ID=11377464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0004227A HU226471B1 (en) | 1997-06-30 | 1998-06-29 | Direct ortho-metalation process for the synthesis of 5-(2-substituted-phenyl)-tetrazol derivatives |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6271375B1 (forum.php) |
| EP (1) | EP0994881B1 (forum.php) |
| JP (1) | JP4128633B2 (forum.php) |
| AT (1) | ATE224395T1 (forum.php) |
| CA (1) | CA2294609C (forum.php) |
| CZ (1) | CZ293277B6 (forum.php) |
| DE (1) | DE69808093T2 (forum.php) |
| ES (1) | ES2182349T3 (forum.php) |
| HU (1) | HU226471B1 (forum.php) |
| IL (1) | IL133249A (forum.php) |
| IT (1) | IT1292437B1 (forum.php) |
| WO (1) | WO1999001459A1 (forum.php) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1197223E (pt) * | 1999-04-28 | 2005-04-29 | Takeda Pharmaceutical | Preventivos/medicamentos/inibidores da progressao de retinopatia simples ou retinopatia pre-proliferativa |
| CA2493597C (en) | 2002-07-26 | 2012-05-08 | Pharmacia Groningen Bv | Method and device for manipulation of an intraocular lens |
| CA2513373A1 (en) * | 2003-01-16 | 2004-08-05 | Teva Pharmaceutical Industries Ltd | Novel synthesis of irbesartan |
| EP1511739B1 (en) * | 2003-03-17 | 2008-04-30 | Teva Pharmaceutical Industries Ltd. | Polymorphs of valsartan |
| US7199144B2 (en) | 2003-04-21 | 2007-04-03 | Teva Pharmaceuticals Industries, Ltd. | Process for the preparation of valsartan and intermediates thereof |
| EP1950204A1 (en) | 2003-03-17 | 2008-07-30 | Teva Pharmaceutical Industries Ltd. | Amorphous form of valsartan |
| EP1556363A2 (en) * | 2003-04-21 | 2005-07-27 | Teva Pharmaceutical Industries Limited | Process for the preparation of valsartan and intermediates thereof |
| EP1618097A1 (en) * | 2003-04-21 | 2006-01-25 | Teva Pharmaceutical Industries Ltd | Process for the preparation of valsartan |
| DE602004010530T2 (de) * | 2003-08-08 | 2008-11-13 | Dipharma Francis S.R.L. | Verfahren zur herstellung von phenyltetrazolderivaten |
| WO2005049587A1 (en) * | 2003-11-21 | 2005-06-02 | Ranbaxy Laboratories Limited | Process for preparation of biphenyl tetrazole |
| US8226977B2 (en) | 2004-06-04 | 2012-07-24 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical composition containing irbesartan |
| US20090124577A1 (en) * | 2004-12-22 | 2009-05-14 | Enantia Si | Intermediate Compounds for the Preparation of an Angiotensin II Receptor Antagonist |
| PT1833801E (pt) * | 2004-12-22 | 2008-08-25 | Algry Quimica S L | Compostos intermediários para a preparação de antagonistas do receptor da angiotensina ii |
| US20070117987A1 (en) * | 2005-07-05 | 2007-05-24 | Viviana Braude | Process for preparing valsartan |
| EP2043607A2 (en) * | 2006-06-23 | 2009-04-08 | Usv Limited | Process for the preparation of micronized valsartan |
| US7943794B2 (en) * | 2008-02-13 | 2011-05-17 | Ranbaxy Laboratories Limited | Processes for the preparation of intermediates of valsartan |
| WO2009125416A2 (en) * | 2008-04-07 | 2009-10-15 | Hetero Research Foundation | Process for preparation of valsartan intermediate |
| WO2012056294A1 (en) | 2010-10-29 | 2012-05-03 | Jubilant Life Sciences Ltd. | An improved process for the preparation of n-pentanoyl-n-[[2'-(1h-tetrazol-5-yi)[1,1'-biphenyl]-4-yi]methyl]-l-valine |
| WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
| US12365654B2 (en) | 2019-12-02 | 2025-07-22 | Harman Finochem Limited | Process for the preparation of highly pure valsartan |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5039814A (en) * | 1990-05-02 | 1991-08-13 | Merck & Co., Inc. | Ortho-lithiation process for the synthesis of 2-substituted 1-(tetrazol-5-yl)benzenes |
| US5149699A (en) | 1991-10-24 | 1992-09-22 | American Home Products Corporation | Substituted pyridopyrimidines useful as antgiotensin II antagonists |
| TW226375B (forum.php) * | 1991-10-24 | 1994-07-11 | American Home Prod | |
| US5256654A (en) | 1991-10-24 | 1993-10-26 | American Home Products Corporation | Substituted pyrrolopyrimidines, azepinopyrimidines and pyridopyrimidines useful as angiotensin II antagonists |
| EP0550313A1 (fr) * | 1991-12-30 | 1993-07-07 | Synthelabo | Nouveaux dérivés de 2-(tétrazol-5-yl)-(1,1'-biphényle), leur préparation et leur utilisation comme intermédiaires de synthèse |
| US5310929A (en) | 1992-08-06 | 1994-05-10 | E. I. Du Pont De Nemours And Company | Prodrugs of imidazole carboxylic acids as angiotensin II receptor antagonists |
| FR2696746B1 (fr) | 1992-10-12 | 1994-11-18 | Synthelabo | Dérivés de l'acide benzèneborinique, leur préparation et leur utilisation comme intermédiaires de synthèse. |
| EP0846117B1 (en) * | 1995-06-07 | 2003-05-14 | Wyeth | Process for preparation of biphenyl derivatives |
| US5760220A (en) | 1995-06-07 | 1998-06-02 | American Home Products Corporation | Process for preparation of biphenyl derivatives |
-
1997
- 1997-06-30 IT IT97MI001544A patent/IT1292437B1/it active IP Right Grant
-
1998
- 1998-06-29 WO PCT/EP1998/003969 patent/WO1999001459A1/en active IP Right Grant
- 1998-06-29 CZ CZ19994774A patent/CZ293277B6/cs not_active IP Right Cessation
- 1998-06-29 AT AT98936398T patent/ATE224395T1/de active
- 1998-06-29 CA CA002294609A patent/CA2294609C/en not_active Expired - Fee Related
- 1998-06-29 ES ES98936398T patent/ES2182349T3/es not_active Expired - Lifetime
- 1998-06-29 JP JP50630899A patent/JP4128633B2/ja not_active Expired - Fee Related
- 1998-06-29 EP EP98936398A patent/EP0994881B1/en not_active Expired - Lifetime
- 1998-06-29 IL IL13324998A patent/IL133249A/xx not_active IP Right Cessation
- 1998-06-29 US US09/445,470 patent/US6271375B1/en not_active Expired - Fee Related
- 1998-06-29 HU HU0004227A patent/HU226471B1/hu not_active IP Right Cessation
- 1998-06-29 DE DE69808093T patent/DE69808093T2/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| ATE224395T1 (de) | 2002-10-15 |
| IT1292437B1 (it) | 1999-02-08 |
| US6271375B1 (en) | 2001-08-07 |
| DE69808093D1 (de) | 2002-10-24 |
| HUP0004227A2 (hu) | 2001-06-28 |
| ITMI971544A0 (forum.php) | 1997-06-30 |
| IL133249A0 (en) | 2001-04-30 |
| WO1999001459A1 (en) | 1999-01-14 |
| CZ293277B6 (cs) | 2004-03-17 |
| EP0994881A1 (en) | 2000-04-26 |
| CZ477499A3 (cs) | 2000-07-12 |
| EP0994881B1 (en) | 2002-09-18 |
| DE69808093T2 (de) | 2003-06-05 |
| JP4128633B2 (ja) | 2008-07-30 |
| CA2294609A1 (en) | 1999-01-14 |
| HUP0004227A3 (en) | 2003-03-28 |
| IL133249A (en) | 2003-12-10 |
| JP2002510314A (ja) | 2002-04-02 |
| CA2294609C (en) | 2008-08-19 |
| ES2182349T3 (es) | 2003-03-01 |
| ITMI971544A1 (it) | 1998-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HU226471B1 (en) | Direct ortho-metalation process for the synthesis of 5-(2-substituted-phenyl)-tetrazol derivatives | |
| EP2481742B1 (en) | Preparation method of aromatic boronate compounds | |
| CN107880079A (zh) | 环状氮杂环双卡宾钯配合物及其制备方法与用途 | |
| AU728147B2 (en) | Method for the preparation of alpha-bromo-lactam derivatives | |
| Dabrowski et al. | An ortho‐lithiated derivative of protected phenylboronic acid: an approach to ortho‐functionalized arylboronic acids and 1, 3‐dihydro‐1‐hydroxybenzo [c][2, 1] oxaboroles | |
| Chapoulaud et al. | Functionalization by metalation of the benzene moiety of benzodiazines. Determination of structures by long-range 1H-15N correlation at natural abundance. Diazines XXV | |
| EP0705249B1 (en) | Palladium catalyzed vinylic substitution reactions with 2-substituted-pyridines | |
| EP1660463B1 (en) | A process for the preparation of phenyltetrazole derivatives | |
| HK1003225B (en) | Palladium catalyzed vinylic substitution reactions with 2-substituted-pyridines | |
| US7977487B2 (en) | Method for producing N,N-bis(pyridin-2ylmethyl)-1,1-bis(pyridin-2-yl)-1-aminoalkane compounds and metal complex salts containing these compounds | |
| Messmer et al. | Direct arylation of tetrazolo [1, 5-a] pyridine and its benzenologues | |
| Szesni et al. | A convenient route to six-membered heterocyclic carbene complexes: Reactions of aminoallenylidene complexes with 1, 3-bidentate nucleophiles | |
| JP5594821B2 (ja) | 新規なアザカリックス［３］ピリジン及びその製造方法 | |
| KR20190108383A (ko) | 옥사미드 및 수소화알루미늄리튬을 이용한 시클렌의 신규 합성법 | |
| Kuehn et al. | A facile access to indigodianiles | |
| USRE38325E1 (en) | Method for the production of tetrakis (pentafluorophenyl) borates | |
| JP2003238572A (ja) | ピリジン−トリ（置換又は非置換フェニル）ボランの製造法 | |
| CN109311907B (zh) | 高纯度普拉格雷的制备方法 | |
| JP3708131B2 (ja) | ホウ酸テトラキス（ペンタフルオロフェニル）の製造方法 | |
| EP4365174A1 (en) | Method for producing benzoxazole derivative having bicyclic piperazine ring or salt thereof, and method for producing material thereof | |
| WO2022176961A1 (ja) | 化合物及び金属錯体 | |
| Brauer et al. | Fluorine effects in organoboranes; formation of cyanoalkyl-bis (trifluoromethyl)-organoborates | |
| JP2002088092A (ja) | 新規な有機金属錯体及びこれを中間体とした高純度有機金属錯体の合成方法 | |
| Shah | Studies of aminyl radicals | |
| CZ297531B6 (cs) | Způsob přímé regioselektivní a enantioselektivní C-alkylace cyklenových, cyklamových a oligoalkylenoligoaminových derivátů |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of definitive patent protection due to non-payment of fees |